We serve Chemical Name:Lauryl Lactate CAS:6283-92-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Lauryl Lactate
CAS.NO:6283-92-7
Synonyms:dodecyl 2-hydroxypropanoate;Lauryl Lactate
Molecular Formula:C15H30O3
Molecular Weight:258.39700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:304.1ºC at 760 mmHg
Density:0.931 g/cm3
Index of Refraction:1.451
PSA:46.53000
Exact Mass:258.21900
LogP:3.83130
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like dodecyl 2-hydroxypropanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Lauryl Lactate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Lauryl Lactate Use and application,dodecyl 2-hydroxypropanoate technical grade,usp/ep/jp grade.
Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. 2-(3,4-dimethoxyphenyl)-7-fluoro-2,3-dihydro-1H-phenothiazin-4(10H)-one 5,5-dioxide manufacturers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. (4S,5R)-4-[3-Benzyloxymethyl-2-(toluene-4-sulfonyl)-oxiranylmethyl]-2,2-di-tert-butyl-5-triethylsilanyloxy-[1,3,2]dioxasilinane suppliers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. Dehydrogenase, formate (Escherichia coli strain K-12 Kohara clone#424 gene hevH) vendor & factory The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. ,After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million.
